This suggests that G&P combination therapy synergistically enhances CD8+ T cell infiltration while reducing immunosuppressive regulatory T cell (Treg) accumulation in the MSS-CRC PDX model. The gene discussed is CD8A; the disease is colorectal carcinoma.